Effects of pemafibrate on glucose metabolism markers and liver function tests in patients with hypertriglyceridemia: a pooled analysis of six phase 2 and phase 3 randomized double-blind placebo-controlled clinical trials

Type 2 Diabetes

Empagliflozin Effectively Lowers Liver Fat Content in Well-Controlled Type 2 Diabetes: A Randomized, Double-Blind, Phase 4, Placebo-Controlled Trial

Diabetes Care.

Kahl S, Gancheva S, Straßburger K, Herder C, Machann J, Katsuyama H, Kabisch S, Henkel E, Kopf S, Lagerpusch M, Kantartzis K, Kupriyanova Y, Markgraf D, van Gemert T, Knebel B, Wolkersdorfer MF, Kuss O, Hwang JH, Bornstein SR, Kasperk C, Stefan N, Pfeiffer A, Birkenfeld AL, Roden M

doi: 10.2337/dc19-0641.

Diabetes - GeneralType 2 DiabetesObesity and Bariatric Surgery

Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study

Diabetologia.

Eriksson JW, Lundkvist P, Jansson PA, Johansson L, Kvarnström M, Moris L, Miliotis T, Forsberg GB, Risérus U, Lind L, Oscarsson J

doi: 10.1007/s00125-018-4675-2.

COMMENTED

Further Publications

Metformin to reduce metabolic complications and inflammation in patients on systemic glucocorticoid therapy: a randomised, double-blind, placebo-controlled, proof-of-concept, phase 2 trial

★ 3 Recommended and commented by Prof. emer. Dr Ulrich Keller, Faculty Member

doi: 10.1016/S2213-8587(20)30021-8.

Type 2 Diabetes

Effect of exenatide twice daily and dapagliflozin alone and in combination on markers of kidney function in obese patients with type 2 diabetes: a prespecified secondary analysis of a randomized controlled clinical trial

Diabetes Obes Metab

van Ruiten CC, van der Aart-van der Beek AB, IJzerman RG, Nieuwdorp M, Hoogenberg K, van Raalte DH, Heerspink HJL

doi: 10.1111/dom.14410

Further Publications

Henagliflozin Monotherapy in Patients with Type 2 Diabetes Inadequately Controlled on Diet and Exercise: A Randomized, Double-blind, Placebo-controlled, Phase 3 Trial

Diabetes Obes Metab

Lu J, Fu L, Li Y, Geng J, Qin L, Ping L, Zheng H, Sun Z, Li Y, Zhang L, Sun Y, Chen D, Qin G, Weiping L, Guo Y, Zhang Y, Liu H, Zhang T, Zou J

doi: 10.1111/dom.14314

COMMENTED

Type 2 Diabetes

Efficacy and Safety of Imeglimin Monotherapy Versus Placebo in Japanese Patients With Type 2 Diabetes (TIMES 1): A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Phase 3 Trial

★ 3 Recommended and commented by Prof. emer. Dr Ulrich Keller, Faculty Member

Diabetes Care

Dubourg J, Fouqueray P, Thang C, Grouin JM, Ueki K

doi: 10.2337/dc20-0763

Type 2 Diabetes

Henagliflozin as add-on therapy to metformin in patients with type 2 diabetes inadequately controlled with metformin: A multicenter, randomized, double-blind, placebo-controlled, phase 3 trial

Diabetes Obes Metab

Weng J, Zeng L, Zhang Y, Qu S, Wang X, Li P, Fu L, Ma B, Ye S, Sun J, Lu W, Liu Z, Chen D, Cheng Z, Liu H, Zhang T, Zou J

doi: 10.1111/dom.14389

Diabetes - GeneralType 2 DiabetesGlycemic Control

Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes: A Randomized Clinical Trial

JAMA.

Davies M, Pieber TR, Hartoft-Nielsen ML, Hansen OKH, Jabbour S, Rosenstock J

doi: 10.1001/jama.2017.14752.

Diabetes - GeneralType 1 DiabetesGlycemic Control

Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial

Lancet Diabetes Endocrinol.

Petrie JR, Chaturvedi N, Ford I, Brouwers MCGJ, Greenlaw N, Tillin T, Hramiak I, Hughes AD, Jenkins AJ, Klein BEK, Klein R, Ooi TC, Rossing P, Stehouwer CDA, Sattar N, Colhoun HM; REMOVAL Study Group

doi: 10.1016/

Related content

Empagliflozin Effectively Lowers Liver Fat Content in Well-Controlled Type 2 Diabetes: A Randomized, Double-Blind, Phase 4, Placebo-Controlled Trial

Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study

Metformin to reduce metabolic complications and inflammation in patients on systemic glucocorticoid therapy: a randomised, double-blind, placebo-controlled, proof-of-concept, phase 2 trial

Effect of exenatide twice daily and dapagliflozin alone and in combination on markers of kidney function in obese patients with type 2 diabetes: a prespecified secondary analysis of a randomized controlled clinical trial

Henagliflozin Monotherapy in Patients with Type 2 Diabetes Inadequately Controlled on Diet and Exercise: A Randomized, Double-blind, Placebo-controlled, Phase 3 Trial

Efficacy and Safety of Imeglimin Monotherapy Versus Placebo in Japanese Patients With Type 2 Diabetes (TIMES 1): A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Phase 3 Trial

Henagliflozin as add-on therapy to metformin in patients with type 2 diabetes inadequately controlled with metformin: A multicenter, randomized, double-blind, placebo-controlled, phase 3 trial

Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes: A Randomized Clinical Trial

Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial